Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1791 results
April 2025
-
Featured News
Related Link - Featured News
-
Ad-hoc Release
test media release format
Abhijeet italic Abhijeet bbbAd hoc announcement pursuant to Art. 53 LRNew indication approximately triples eligible patient population, allowing Pluvicto® to be used after one androgen receptor… -
Ad-hoc Release
test media release format
Abhijeet italic Abhijeet bbbAd hoc announcement pursuant to Art. 53 LRNew indication approximately triples eligible patient population, allowing Pluvicto® to be used after one androgen receptor…
December 2024
November 2024
-
Biologist to Head-hunter
I sometimes overlook what I’ve achieved or overcome to arrive at this point in my career. The opportunities I’ve embraced, the advice I’ve received and the heartfelt decisions I’ve made. So sharing my journey with you was an opportunity to pause and reflect, strengthening my belief that change is not always easy, but it can be very rewarding.
-
Addressing unmet needs for inherited neuromuscular diseases
Novartis has acquired Kate Therapeutics to further enhance and strengthen our ongoing efforts to advance gene therapies for patients.
October 2024
-
Official partner of the Eurovision Song Contest 2025
We’re thrilled to announce that Novartis, a proudly Swiss company, is an official partner of the Eurovision Song Contest 2025, hosted in our headquarters city of Basel, Switzerland.
-
My journey to Novartis: Finding my purpose and passion
When I first joined Novartis, I was nervous yet open to new experiences. I did not have experience in the pharmaceutical industry, and the dynamics and ways of working in marketing were completely different from what I was used to. But what sealed the deal for me was a conversation with my then manager who told me that the purpose I would feel and impact I would have would be unique. And she was right.
August 2024
-
Featured News
Novartis employs creative deal structure to establish Borealis Biosciences – divests legacy Chinook site, invests to form new company and engages in R&D collaboration
Novartis announced it has partnered with Versant Ventures (Versant) to form Borealis Biosciences (Borealis), an independent, discovery-stage biotechnology company based in Vancouver, Canada, focused on developing next-generation xRNA-based medicines for kidney diseases. xRNA, a core technology platform for Novartis, can target the body’s natural mRNA to modulate the production of proteins that cause disease.
-
Negative impact of the IRA on patient access to innovative treatments
At Novartis, we are constantly pushing the limits of science to develop and deliver transformative medicines that fight disease and help people live life on their terms.
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 150
- › Next page